Study #2019-0922
A Phase I, Multicenter, Open-Label, Dose Escalation Study of a Novel Bruton fs Tyrosine Kinase Inhibitor, ICP-022, in Patients with Relapsed/Refractory B-Cell Malignancies.
MD Anderson Study Status
Not Accepting
Treatment Agent
Orelabrutinib (ICP-022)
Description
This is a Phase I/II, multicenter, open-label study to evaluate the safety, efficacy, tolerability, and pharmacokinetics of a novel BTK inhibitor, Orelabrutinib (ICP-022) in Patients with B-cell malignancies. The study contains two parts, Part 1 (dose escalation) and Part 2 (dose expansion).
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Part 1：r/r B-cell Malignancies, Part 2：B-cell Malignancies
Study phase:
Physician name:
Michael Wang
Department:
Lymphoma/Myeloma
For general questions about clinical trials:
1-844-955-5036
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.